PMID- 33894731
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2224-5839 (Electronic)
IS  - 2224-5820 (Linking)
VI  - 10
IP  - 4
DP  - 2021 Apr
TI  - Use of dexamethasone and a 5-HT3 receptor antagonist with or without aprepitant 
      to prevent chemotherapy-induced nausea and vomiting among patients with lung 
      cancer who are treated with platinum-based chemotherapy: a systematic review and 
      meta-analysis of randomized controlled trials.
PG  - 4308-4319
LID - 10.21037/apm-20-2290 [doi]
AB  - BACKGROUND: Researchers have not clearly determined whether adding aprepitant 
      (ADH) to dexamethasone and one 5-HT3 receptor antagonist (DH) is clinically 
      effective at preventing chemotherapy-induced nausea and vomiting (CINV) among 
      patients with lung cancer (LC) treated with platinum-based chemotherapy (PBC). 
      Therefore, we conducted a meta-analysis to examine the efficacy and safety of ADH 
      and DH. METHODS: We searched the PubMed, ScienceDirect, Cochrane Library, and 
      Scopus databases, among others, for relevant studies. The primary outcomes were 
      the complete response (CR) and the no nausea rate (NNR). The secondary endpoints 
      were the number of patients who needed rescue antiemetic treatment (RAT), adverse 
      events (AEs), and the Functional Living Index Emesis (FLIE) score. RESULTS: We 
      initially screened 2,118 articles; ultimately, four randomized controlled trials 
      (RCTs) with 518 patients were included. The ADH group had a superior overall CR 
      [risk ratio (RR): 1.16 (1.06, 1.27), P=0.002] and a lower number of patients who 
      needed RAT [RR: 0.44 (0.29, 0.65), P<0.0001]. The ADH group also had a better 
      overall NNR [RR: 1.11 (0.97, 1.26), P=0.12] and delayed CR [RR: 1.12 (0.97, 
      1.31), P=0.13]. No significant differences were observed in acute CR, acute NNR, 
      or delayed NNR. In the subgroup analysis of the overall CR and NNR, ADH was 
      superior in certain clinical characteristics (China, cisplatin-based 
      chemotherapy, 2nd-generation 5-HT3 receptor antagonist, ADC <50%, and Eastern 
      Cooperative Oncology Group (ECOG) score of 0-2). No significant differences in 
      the AEs characterized as hematological or nonhematological toxicity were observed 
      between the groups. CONCLUSIONS: Compared with DH, ADH appears to be superior at 
      preventing CINV and achieving a better CR among patients with LC treated with 
      PBC.
FAU - He, Mengyu
AU  - He M
AD  - Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China; Jiangxi Medical College, Nanchang University, 
      Nanchang, China.
FAU - Xu, Ruoxin
AU  - Xu R
AD  - Jiangxi Medical College, Nanchang University, Nanchang, China.
FAU - Liu, Miaowen
AU  - Liu M
AD  - Jiangxi Medical College, Nanchang University, Nanchang, China.
FAU - Zhang, Yixuan
AU  - Zhang Y
AD  - Jiangxi Medical College, Nanchang University, Nanchang, China; Department of 
      Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
FAU - Yi, Fengming
AU  - Yi F
AD  - Department of Oncology, The Second Affiliated Hospital of Nanchang University, 
      Nanchang, China.
FAU - Wei, Yiping
AU  - Wei Y
AD  - Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
FAU - Liu, Qing
AU  - Liu Q
AD  - Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
FAU - Zhang, Wenxiong
AU  - Zhang W
AD  - Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20210415
PL  - China
TA  - Ann Palliat Med
JT  - Annals of palliative medicine
JID - 101585484
RN  - 0 (Antiemetics)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Morpholines)
RN  - 0 (Receptors, Serotonin, 5-HT3)
RN  - 1NF15YR6UY (Aprepitant)
RN  - 49DFR088MY (Platinum)
RN  - 7S5I7G3JQL (Dexamethasone)
SB  - IM
MH  - *Antiemetics/therapeutic use
MH  - *Antineoplastic Agents/adverse effects
MH  - Aprepitant/therapeutic use
MH  - China
MH  - Dexamethasone/therapeutic use
MH  - Humans
MH  - *Lung Neoplasms/drug therapy
MH  - Morpholines/therapeutic use
MH  - Nausea/chemically induced/drug therapy/prevention & control
MH  - Platinum/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Receptors, Serotonin, 5-HT3/therapeutic use
MH  - Vomiting/chemically induced/drug therapy/prevention & control
OTO - NOTNLM
OT  - Aprepitant
OT  - chemotherapy
OT  - lung cancer (LC)
OT  - meta-analysis
OT  - nausea
OT  - vomiting
EDAT- 2021/04/26 06:00
MHDA- 2021/05/15 06:00
CRDT- 2021/04/25 20:17
PHST- 2020/11/17 00:00 [received]
PHST- 2021/02/24 00:00 [accepted]
PHST- 2021/04/26 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2021/04/25 20:17 [entrez]
AID - apm-20-2290 [pii]
AID - 10.21037/apm-20-2290 [doi]
PST - ppublish
SO  - Ann Palliat Med. 2021 Apr;10(4):4308-4319. doi: 10.21037/apm-20-2290. Epub 2021 
      Apr 15.